|Articles|May 31, 2012

Bevacizumab improves BCVA and central macular thickness in CSME patients

Multiple injections of bevacizumab improve best-corrected visual acuity (BCVA) and central macular thickness in patients with persistant clinically significant macular oedema (CSME)

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.


Latest CME